SU5416 in Treating Patients With Refractory or Relapsed Multiple Myeloma

NCT00006013 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma and Plasma Cell Neoplasm

Interventions

DRUG: semaxanib

Sponsor

Fox Chase Cancer Center

Collaborators

[object Object]